Results 201 to 210 of about 39,242 (358)

The antigenicity of serum proteins and their role in xenograft rejection [PDF]

open access: yes, 1996
Celli, S   +9 more
core  

Has early mortality following single‐unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan

open access: yesBritish Journal of Haematology, EarlyView.
The 100‐day non‐relapse mortality after single‐unit cord blood transplantation significantly declined from 19.6% (2003–2007) to 9.5% (2018–2022), while the 3‐year overall survival improved from 38.8% to 54.4%. Haematopoietic recovery rates improved steadily, with neutrophil engraftment reaching 89.6% and platelet engraftment 78.0% in the most recent ...
Takaaki Konuma   +19 more
wiley   +1 more source

Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study

open access: yesBritish Journal of Haematology, EarlyView.
Summary The efficacy of ciclosporin (CsA) to treat transfusion‐independent non‐severe aplastic anaemia (TI‐NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI‐NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI‐NSAA aged ≥16.
Ken Ishiyama   +14 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy